Francisco A Almeida1, Roberto F Casal2, Carlos A Jimenez3, George A Eapen3, Mateen Uzbeck4, Mona Sarkiss5, David Rice6, Rodolfo C Morice3, David E Ost3. 1. Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, Cleveland, OH. 2. Department of Pulmonary and Critical Care Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX. 3. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. The Department of Pulmonary Medicine, Our Lady of Lourdes and Beaumont Hospitals, Dublin, Ireland. 5. Department of Anesthesia, The University of Texas MD Anderson Cancer Center, Houston, TX. 6. Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: dost@mdanderson.org.
Abstract
BACKGROUND: Evidence-based guidelines recommend mediastinal sampling as the first invasive test in patients with suspected lung cancer and mediastinal adenopathy. The goal of this study was to assess practice patterns and outcomes of diagnostic strategies in this patient population. METHODS: We conducted a retrospective analysis of all patients in 2009 who had mediastinal adenopathy without distant metastatic disease to determine whether guideline-consistent care was delivered. Guideline-consistent care was defined as mediastinal lymph node sampling being performed as part of the first invasive procedure. RESULTS: One hundred thirty-seven patients were included. Guideline-consistent care was provided in 30 cases (22%). Patients receiving guideline-consistent care had fewer invasive tests than patients with guideline-inconsistent care (1.3 ± 0.5 tests/patient vs 2.3 ± 0.5 tests/patient, respectively; P < .0001) and fewer complications (0 of 30, 0% vs 18 of 108, 17%; P = .01). Most of the complications (16 of 18) were related to CT image-guided needle biopsy. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was sufficient to guide treatment decisions without any other invasive tests in 88 patients (64%). Although not all the complications and costs due to CT image-guided biopsies could have been avoided, roughly two-thirds could have been eliminated by just changing the testing sequence. CONCLUSION: Quality gaps in lung cancer staging in patients with mediastinal adenopathy are common and lead to unnecessary testing and increased complications. In patients with suspected lung cancer without distant metastatic disease with mediastinal adenopathy, EBUS-TBNA should be the first test.
BACKGROUND: Evidence-based guidelines recommend mediastinal sampling as the first invasive test in patients with suspected lung cancer and mediastinal adenopathy. The goal of this study was to assess practice patterns and outcomes of diagnostic strategies in this patient population. METHODS: We conducted a retrospective analysis of all patients in 2009 who had mediastinal adenopathy without distant metastatic disease to determine whether guideline-consistent care was delivered. Guideline-consistent care was defined as mediastinal lymph node sampling being performed as part of the first invasive procedure. RESULTS: One hundred thirty-seven patients were included. Guideline-consistent care was provided in 30 cases (22%). Patients receiving guideline-consistent care had fewer invasive tests than patients with guideline-inconsistent care (1.3 ± 0.5 tests/patient vs 2.3 ± 0.5 tests/patient, respectively; P < .0001) and fewer complications (0 of 30, 0% vs 18 of 108, 17%; P = .01). Most of the complications (16 of 18) were related to CT image-guided needle biopsy. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was sufficient to guide treatment decisions without any other invasive tests in 88 patients (64%). Although not all the complications and costs due to CT image-guided biopsies could have been avoided, roughly two-thirds could have been eliminated by just changing the testing sequence. CONCLUSION: Quality gaps in lung cancer staging in patients with mediastinal adenopathy are common and lead to unnecessary testing and increased complications. In patients with suspected lung cancer without distant metastatic disease with mediastinal adenopathy, EBUS-TBNA should be the first test.
Authors: Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart Journal: Ann Thorac Surg Date: 2005-12 Impact factor: 4.330
Authors: Frank C Detterbeck; Michael A Jantz; Michael Wallace; Johan Vansteenkiste; Gerard A Silvestri Journal: Chest Date: 2007-09 Impact factor: 9.410
Authors: Gerard A Silvestri; Michael K Gould; Mitchell L Margolis; Lynn T Tanoue; Douglas McCrory; Eric Toloza; Frank Detterbeck Journal: Chest Date: 2007-09 Impact factor: 9.410
Authors: I Garcia-Olivé; E Monsó; F Andreo; J Sanz-Santos; M Taron; M A Molina-Vila; M Llatjós; E Castellà; T Moran; J Bertran-Alamillo; C Mayo-de-Las-Casas; C Queralt; R Rosell Journal: Eur Respir J Date: 2009-07-30 Impact factor: 16.671
Authors: Oisin J O'Connell; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Ray Lazarus; Benjamin Young; Yu Chen; Roy Semaan; Timothy M Saettele; Joseph Cicenia; Harmeet Bedi; Corrine Kliment; Liang Li; Sonali Sethi; Javier Diaz-Mendoza; David Feller-Kopman; Juhee Song; Thomas Gildea; Hans Lee; Horiana B Grosu; Michael Machuzak; Macarena Rodriguez-Vial; George A Eapen; Carlos A Jimenez; Roberto F Casal; David E Ost Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Farhood Farjah; David K Madtes; Douglas E Wood; David R Flum; Megan E Zadworny; Rachel Waworuntu; Billanna Hwang; Michael S Mulligan Journal: J Thorac Cardiovasc Surg Date: 2015-08-06 Impact factor: 5.209
Authors: Michael A Pritchett; Stéphanie Schampaert; Joris A H de Groot; Charles C Schirmer; Imramsjah van der Bom Journal: J Bronchology Interv Pulmonol Date: 2018-10
Authors: Akash Verma; Albert Y H Lim; Dessmon Y H Tai; Soon Keng Goh; Ai Ching Kor; Dokeu Basheer A A; Akhil Chopra; John Abisheganaden Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.817